Advertisement
UK markets close in 49 minutes

  • FTSE 100

    8,140.81
    +61.95 (+0.77%)
     

  • FTSE 250

    19,835.63
    +233.65 (+1.19%)
     

  • AIM

    755.68
    +2.56 (+0.34%)
     

  • GBP/EUR

    1.1675
    +0.0018 (+0.16%)
     

  • GBP/USD

    1.2483
    -0.0028 (-0.22%)
     

  • Bitcoin GBP

    51,283.74
    +350.04 (+0.69%)
     

  • CMC Crypto 200

    1,342.95
    -53.59 (-3.73%)
     

  • S&P 500

    5,100.81
    +52.39 (+1.04%)
     

  • DOW

    38,240.18
    +154.38 (+0.41%)
     

  • CRUDE OIL

    83.69
    +0.12 (+0.14%)
     

  • GOLD FUTURES

    2,350.00
    +7.50 (+0.32%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,190.06
    +272.78 (+1.52%)
     

  • CAC 40

    8,108.22
    +91.57 (+1.14%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Pfizer-BioNTech potential COVID-19 vaccine shows promise in additional data

Reuters Staff
Updated ·1-min read

By Reuters Staff

(Reuters) - German biotech firm BioNTech and U.S. drugmaker Pfizer on Monday reported additional data from their experimental COVID-19 vaccine that showed it was safe and induced an immune response in patients.

The companies said the data also demonstrated an induction of high level of T-cell responses against the novel coronavirus.

More than 150 possible vaccines are being developed and tested around the world to try to stop the pandemic. There are 23 candidates in human clinical trials, including from Moderna and AstraZeneca Plc.

Experts have cautioned a safe and effective vaccine will take 12-18 months to develop.

ADVERTISEMENT

The results were disclosed from a trial in Germany testing 60 healthy volunteers, and come after the companies earlier this month reported data from a corresponding early-stage trial in the United States.

The trial showed that volunteers given two doses of the vaccine produced virus-neutralizing antibodies, similar to the U.S. trial.

The data is available on an online preprint server at medrxiv (https://bit.ly/2OJ2qD6) and is undergoing scientific peer-review for potential publication, the companies said.